An Enhanced Artificial Intelligence Breast MRI Scanning System (IntelliScan)

增强型人工智能乳腺 MRI 扫描系统 (IntelliScan)

• 批准号: 104192
• 金额: $ 105.48万
• 依托单位: FIRST OPTION SOFTWARE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104192
• 关键词: Enhanced; Artificial; Intelligence; Breast; MRI

"Breast cancer is the most common type of cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2015 (second most common cancer overall). This represents about 12% of all new cancer cases and 25% of all cancers in women. According to the World Health Organisation (Global Heath Estimates 2013), over 50% of breast cancer cases and 42% of deaths occur in developed countries. This includes the UK, where one in 5 cases of breast cancer results in a fatality.This project therefore seeks to develop INTELLISCAN, an Artificial Intelligence, machine learning enhanced breast MRI scanning system for use as a highly efficient, more accurate breast cancer screening tool. Our technology applies computer based image processing to deliver improved, instant, automated anomaly detection of breast MRI scans. "

乳腺癌是全球女性最常见的癌症类型，2015年诊断出近170万例新病例（总体上是第二大常见癌症）。这约占所有新发癌症病例的12%和所有女性癌症的25%。根据世界卫生组织（2013年全球健康估计），超过50%的乳腺癌病例和42%的死亡发生在发达国家。在英国，每5例乳腺癌中就有1例死亡。因此，该项目旨在开发INTELLISCAN，一种人工智能，机器学习增强的乳腺MRI扫描系统，作为一种高效，更准确的乳腺癌筛查工具。我们的技术应用基于计算机的图像处理来提供改进的、即时的、自动化的乳房MRI扫描异常检测。"